- Home
- PLXS vs CELC Comparison
PLXS vs CELC Comparison
Compare PLXS & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLXS
- CELC
- Stock Information
- Founded
- PLXS 1979
- CELC 2011
- Country
- PLXS United States
- CELC United States
- Employees
- PLXS N/A
- CELC N/A
- Industry
- PLXS Electrical Products
- CELC Medical Specialities
- Sector
- PLXS Technology
- CELC Health Care
- Exchange
- PLXS Nasdaq
- CELC Nasdaq
- Market Cap
- PLXS 3.8B
- CELC 3.1B
- IPO Year
- PLXS 1986
- CELC 2017
- Fundamental
- Price
- PLXS $143.89
- CELC $74.11
- Analyst Decision
- PLXS Buy
- CELC Strong Buy
- Analyst Count
- PLXS 4
- CELC 5
- Target Price
- PLXS $157.50
- CELC $69.40
- AVG Volume (30 Days)
- PLXS 181.4K
- CELC 1.4M
- Earning Date
- PLXS 10-22-2025
- CELC 11-12-2025
- Dividend Yield
- PLXS N/A
- CELC N/A
- EPS Growth
- PLXS 56.11
- CELC N/A
- EPS
- PLXS 6.26
- CELC N/A
- Revenue
- PLXS $4,032,966,000.00
- CELC N/A
- Revenue This Year
- PLXS $10.09
- CELC N/A
- Revenue Next Year
- PLXS $5.36
- CELC N/A
- P/E Ratio
- PLXS $23.02
- CELC N/A
- Revenue Growth
- PLXS 1.82
- CELC N/A
- 52 Week Low
- PLXS $103.43
- CELC $7.58
- 52 Week High
- PLXS $172.89
- CELC $83.00
- Technical
- Relative Strength Index (RSI)
- PLXS 50.61
- CELC 64.02
- Support Level
- PLXS $137.67
- CELC $71.06
- Resistance Level
- PLXS $146.36
- CELC $79.97
- Average True Range (ATR)
- PLXS 5.00
- CELC 5.13
- MACD
- PLXS -0.46
- CELC 0.11
- Stochastic Oscillator
- PLXS 41.38
- CELC 53.43
About PLXS Plexus Corp.
Plexus Corp is a U.S based Electronic Manufacturing Services company that provides a range of services, from conceptualization and design to fulfilling orders and providing sustaining solutions, such as replenishment and refurbishment. The company's segments comprise AMER, APAC,ge and EMEA.
About CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.